Brief: Theriva Biologics Announces Positive Recommendation On Phase 2B Trial Of Vcn-01 In Combination With Chemotherapy For Metastatic Pancreatic Ductal Adenocarcinoma
07/02/2024 13:14
Feb 7 (Reuters) - Theriva Biologics Inc TOVX.A :
* THERIVA BIOLOGICS ANNOUNCES POSITIVE RECOMMENDATION FROM
THE
INDEPENDENT DATA MONITORING COMMITTEE OF VIRAGE, THE PHASE 2B
CLINICAL TRIAL OF VCN-01 IN COMBINATION WITH CHEMOTHERAPY FOR
METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
* THERIVA BIOLOGICS INC - VIRAGE REMAINS ON TRACK TO
COMPLETE
ENROLLMENT IN FIRST HALF OF 2024
* THERIVA BIOLOGICS INC - INDEPENDENT DATA MONITORING
COMMITTEE
(IDMC) RECOMMENDED CONTINUATION OF VIRAGE WITH NO SAFETY
CONCERNS RAISED
Source text for Eikon: ID:nGNE6mlfj1
Further company coverage: TOVX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theriva Biologics
See all newsTheriva Biologics Q2 net loss narrows on lower R&D costs, expenses
Brief: Theriva™ Biologics Announces Upcoming Presentation Of Additional Data From The Virage Phase 2B Clinical Trial Of Vcn-01 In Metastatic Pancreatic Cancer At Aacr 2026 Annual Meeting
Brief: Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications
Brief: Theriva Biologics Implements 32% Workforce Reduction - SEC Filing
Brief: Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025